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Abstract The addition of insulin or insulin-like growth factor I 
(IGF-I) to RIE-I cells increased the expression of the primary 
response gene cMGI; dose-response analysis suggested that this 
effect was mediated largely through type I IGF receptors. Insu- 
lin/IGF-I did not affect the expression of the cMGl-related genes 
TISI 1 and TISIId, whereas epidermal growth factor, angioten- 
sin II or 12-O-tetradecanoyl phorbol-lJ-acetate stimulated the 
expression of all three genes. Incubation with wortmannin (WM) 
prevented the insulin/IGF-l-induced elevation of cMGI mRNA, 
but not that induced by the other mitogens or the stimulation of 
mitogen-activated protein kinase by insulin. We conclude that 
WM-sensitive phosphatidylinositol 3-kinase may be involved in 
the specific stimulation of cMGI expression by insulin/IGF-l. 
Key words: Insulin; Primary response gene; 
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I. Introduction 
Growth factors and hormones timulate rapid and transient 
increases in the expression of members of the class of genes 
termed primary response genes (for review see [1]). Several of 
these genes, such as the proto-oncogenes c-fos and c-jun, en- 
code nuclear proteins that have been demonstrated to be either 
transcription factors or transcriptional modulators, and may 
thus be important in coordinating the genetic changes that 
result from cellular stimulation. Using differential hybridisa- 
tion screening of a rat intestinal epithelial cell line (RIE-1) 
stimulated with epidermal growth factor (EGF), we identified 
a primary response gene named cMG1 [2,3]. This is one of three 
members of a new family of genes, which code for proteins 
containing a markedly conserved 67-amino acid region includ- 
ing two potential C3 H zinc-finger-like domains [4]. A second 
member of the family, named TIS11 [4], TTP [5] or Nup475 [6], 
has indeed been shown to bind zinc, and is also localised to the 
nucleus [6], which is consistent with a role as a transcriptional 
regulator. T1S11 mRNA is elevated from a low basal level by 
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various agonists [4-6], while cMG1 (mouse TISllb) is also 
stimulated but from a more readily detected basal level [4,7]; 
less is known about the third family member, TIS1 ld, which 
showed only limited stimulation by phorbol ester in 3T3 cells 
[4]. Insulin and insulin-like growth factor-I (IGF-I) were among 
the agonists which stimulated cMG1 expression i  RIE-1 cells 
and Swiss 3T3 cells [7], while TIS11/TTP was identified as an 
insulin-stimulated gene in transfected NIH-3T3 cells expressing 
high numbers of insulin receptors [5]. These observations raised 
the possibility that the cMGI gene family might be particularly 
relevant o the action of insulin/IGF-I. We have therefore in- 
vestigated the specificity and mechanism of activation of this 
gene family by insulin/IGF-I in RIE-1 cells. 
Signalling responses to many polypeptide agonists are initi- 
ated by the intrinsic protein-tyrosine kinase activity of their 
receptors [8-10]. Ligand-stimulated auto-phosphorylation of 
the receptors for platelet-derived growth factor and EGF, on 
tyrosine residues within specific target sequences, induces inter- 
actions with signalling molecules which are then activated by 
conformational change and/or phosphorylation [8,9]. A similar 
targeting mechanism occurs at the insulin and type 1 IGF 
receptors, except that the signalling molecules bind to 
phosphotyrosyl targets on an adaptor molecule [8,10]. The 
major adaptor is IRS-1, which is the principal substrate for the 
receptor tyrosine kinases [10], although other adaptors allow 
certain responses to occur after the targeted eletion of the 
IRS-1 gene [11,12]. Among the best characterised of the sig- 
nalling pathways thus recruited to IRS-1 is the so-called mito- 
gen-activated protein kinase (MAP kinase) pathway. The MAP 
kinase ERK-2 is activated by receptor tyrosine kinases via a 
series of components ermed Grb2, Sos, p21 r"~, Raf-1 and MAP 
kinase kinase, and a number of targets for this pathway are 
known [9,10,13]. Another signalling molecule that is activated 
when bound to IRS-1 is phosphatidylinositol 3-kinase (PI3K) 
[10,14,15], and insulin and IGF-I induce a marked increase in 
cellular phosphatidylinositol 3,4,5-trisphosphate (PI-3,4,5-P3), 
the principal molecular species generated on activation of this 
enzyme [16,17]. Receptor-activated PI3K is inhibited by the 
fungal metabolite wortmannin (WM), with a substantial degree 
of specificity compared to various other lipid kinases [18]. The 
use of WM, an unrelated inhibitor LY294002, inhibitory anti- 
bodies and mutated components have implicated PI3K (and, 
presumably, its products) in the stimulation of cellular proc- 
esses such as glucose transport, membrane ruffling, c-los ex- 
pression and DNA synthesis [15,19-21], although the interme- 
diate regulatory steps are less well understood than the MAP 
kinase pathway. We have used WM to investigate the possible 
involvement of PI3K in the stimulation of cMG1 expression. 
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2. Experimental 
2.1. Materials 
Reagents for cell culture were obtained from ICN-Flow and Imperial 
Laboratories. Insulin, EGF, AII, 12-O-tetradecanoyl phorbol-13-ace- 
tate (TPA), 3-isobutyl-l-methylxanthine (IBMX) and forskolin were 
obtained from sources described previously [7,22], IGF-I was from 
Bachem, and WM (Sigma) was donated by Dr P.T. Hawkins. The 
cDNA probe for cMG1 was a 1262-bp EcoRI fragment spanning the 
coding sequence [3]. The probe for TISI 1 (TTP) was a 1.8-kb HindIIII 
XbaI fragment [5] provided by Dr P. Blackshear (Howard Hughes 
Medical Institute, Duke University), and the probe for TIS1 ld was a 
1.2-kb SalI fragment [4] provided by Dr H. Herschman (Laboratory of 
Biomedical and Environmental Sciences, UCLA). 
2.2. Methods 
Stock cultures of RIE-1 cells were maintained and passaged as de- 
scribed previously [7,22]. Cells were grown on 9-cm dishes for 10-15 
days in DMEM containing 5% newborn calf serum, by which time they 
were confluent and quiescent. If required, cellular protein kinase C 
(PKC) was depleted by incubation overnight with 300 nM TPA; this 
treatment reduces PKC in this cell line to a level undetectable by 
Western blotting [22]. In most of the experiments described, the mito- 
gens were added directly to the cells in the depleted growth medium. 
In other experiments, the cells were rinsed and equilibrated in fresh 
serum-free DMEM containing BSA (1 mg/ml) for 30 min before adding 
the mitogens, in order to remove IGF-binding proteins. The two proto- 
cols gave similar results for all treatments except IGF-I, which had no 
effect unless the medium was changed as described. After incubation 
of the cells with the required treatments at 37°C, the medium was 
aspirated and the cells were lysed on the dish by the addition of 0.6 ml 
(per dish) of denaturing solution (solution D of [23]). The cell lysates 
were scraped into centrifuge tubes, and total RNA was isolated [23] and 
stored at - 20°C. 
Northern blotting, the labelling of cDNA probes using [a-32P]dCTP 
(ICN), hybridisation to Hybond N filters, and washing of the filters, 
were all performed as described previously [7]. Filters were generally 
exposed to X-ray film for up to 24 h at - 70°C with intensifier screens, 
except hat a longer exposure (up to 7 days) was required for TIS11, 
which appears to be stimulated to a lower maximum level in these cells 
than in, for example, Swiss 3T3 cells (A.N.C., unpublished ata). Au- 
toradiographs were scanned using a Chromoscan 3 densitometer 
(Joyce-Loebl), and analysis of glyceraldehyde phosphate dehydroge- 
nase (GAPDH) mRNA expression was used to account for minor 
differences in loading. 
The analysis of the MAP kinase ERK-2 by Western blotting was 
performed essentially as described previously [22], using monoclonal or 
affinity-purified polyclonal anti-ERK-2 antibodies (Transduction Lab- 
oratories) followed by detection using ECL (Amersham); a low ratio 
of bis-acrylamidelacrylamide (1:60) was used in the gels, which en- 
hanced the separation of the different phosphorylated forms of ERK-2. 
3. Results and discussion 
When insulin was added to confluent, quiescent RIE-1 cells, 
it stimulated an elevation of cMG1 mRNA,  that was 2-3-fold 
above basal after 1 h and decreased rather slowly thereafter 
(Fig. la). In contrast, the levels of T IS l l  and TIS1 ld mRNAs 
in the same samples were not affected by the incubation with 
insulin (Fig. la). However, these two genes could be activated 
in RIE-1 cells, since each of the other mitogens tested (EGF, 
AII and TPA) stimulated the expression of each of the three 
members of the family (Fig. 1). IGF- I  also had no effect on 
T IS l l  or TIS1 ld mRNA levels, and was 10-100-fold more 
potent than insulin in stimulating cMG1 expression (Fig. lc), 
suggesting that the effects of both agonists were mediated 
largely through type 1 IGF receptors (although a contribution 
from insulin receptors cannot be excluded). Although there are 
differences between the times of maximal induction of the three 
genes by various agonists in these and other cells ([4] and 
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Fig. 1. Stimulation ofcMGl, TIS11 and TIS1 ld in RIE-1 cells. Conflu- 
ent, quiescent cells were incubated at 37°C for: (a) 1-4 h with insulin 
(1 ,ug/ml) or EGF (40 pg/ml); (b) 1 h with EGF (40 pg/ml), AII (100 
nM) or TPA (30 nM); (c) 1 h with insulin or IGF-I at the concentrations 
shown; control cells received an equivalent volume of serum-free me- 
dium. RNA was prepared as described in the text, aliquots (10 pg) were 
analysed by Northern blotting, and the blots were probed sequentially 
for cMG1, TIS11 and TIS1 ld. Similar results were obtained in at least 
two other experiments with each agonist. In (c), the expression of 
cMGI, corrected for minor differences in loading revealed by reprobing 
the blots for GAPDH, is shown relative to that in control cells; mean 
values from 2 experiments. 
A.N.C., unpublished ata), this did not explain the observed 
lack of effect of insulin/IGF-I on TISI1 or TIS1 ld in RIE-1 
cells: in three separate experiments no elevation of these 
mRNAs was observed in incubations ranging from 15 to 240 
min with insulin (Fig. la and data not shown). It therefore 
appears that the receptors for insulin/IGF-I are coupled to the 
inducible expression of cMGI  but not of TIS11 or TIS1 ld in 
these cells. Comparison with published work indicates that the 
stimulation ofTIS11 by insulin may only occur in cells express- 
ing high numbers of insulin receptors, such as NIH-3T3 cells 
over-expressing transfected insulin receptors or 3T3-L1 cells 
after conversion to adipocytes [5]. Similarly, c-los activation by 
insulin is well documented in these cell types [20,24] and in 
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principal insulin-responsive tissues in vivo [25]. However, cells 
such as 3T3 fibroblasts and RIE-1 cells mount substantial re- 
sponses to insulin/IGF-I without significant changes in the level 
of c-fos mRNA compared with the effects of other mitogens 
([24] and A.N.C., unpublished data). Thus, it appears that 
cMG 1 may be unusually sensitive to activation by insulin/|GF- 
I. 
In previous work, we showed that the addition of cyclic 
AMP-elevating agents such as forskolin plus IBMX markedly 
reduced the stimulation of cMG1 expression induced by EGF, 
and that the depletion of cellular PKC by pretreatment with 
TPA blocked the effect of AI I  on cMG1 expression but not that 
of EGF  [7]. We have now found that the elevation of cyclic 
AMP also inhibited the stimulation of cMGI  mRNA by insu- 
lin, whereas the depletion of PKC had little effect (Table 1). 
Thus, the stimulation of cMG1 expression by insulin shows a 
similar inhibition profile to that induced by EGF, raising the 
possibility that the two receptor tyrosine kinases activate cMG1 
expression by similar signalling pathways. 
The activation of PI3K has been implicated in the regulation 
of various intracellular events by insulin, including the induc- 
tion of c-fos (see Introduction). We therefore investigated the 
possible involvement of PI3K in the elevation ofcMG1 mRNA 
by insulin/IGF-I in RIE-1 cells. The addition of WM markedly 
inhibited the stimulation of cMG1 mRNA by insulin/IGF-I 
(Fig. 2). Complete inhibition was obtained at a dose of WM 
(100 nM) which has been shown to give maximal inhibition of 
PI3K in other cell types without affecting other lipid kinases 
[18], and the specificity of WM action in the current study was 
indicated by two features: first, WM did not block the stimula- 
tion of cMG1 or TIS11 mRNA induced by TPA, EGF  or AI I  
(Fig. 2), indicating that it did not have a general effect on 
signalling pathways stimulating ene expression; secondly, it 
did not affect other aspects of insulin-induced signalling, such 
as the phosphorylation of ERK-2 (see below). Thus, PI3K may 
be involved in the signalling pathway by which insulin/IGF-I 
stimulate cMG1 expression, but it is not required for the activa- 
tion of the three members of the cMG1 family by other agonists 
including EGF. Previous studies have shown that the EGF 
receptor lacks the high-affinity target sequence for PI3K re- 
Table 1 
Effect of cyclic AMP elevation and PKC depletion on insulin-stimu- 
lated cMG1 expression i  RIE-1 cells 
Pretreatment cMG1 expression (% of control) 
control insulin 
Control 100 167 
Forskolin/IBMX 117 109 
Control 100 166 
PKC depletion 100 152 
Confluent, quiescent cells were pre-incubated for 10 rain at 37°C with 
forskolin (10 ,uM) plus IBMX (50/IM); some cells were pretreated 
overnight with TPA (300 nM) to down-regulate PKC; control cells were 
given 0.1% (v/v) DMSO. Insulin (1 pg/ml) or vehicle was then added, 
and the incubation was continued at 37°C for 60 rain. RNA was 
prepared as described in the text, and aliquots (10 gig) were analysed 
by Northern blotting. The results shown are the expression of 
cMG1 mRNA relative to that in control cells, and are mean values from 
three experiments for cyclic AMP and two experiments for PKC 
depletion. 
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Fig. 2. Inhibition by WM of insulin-stimulated cMG1 expression in 
RIE-1 cells. Confluent, quiescent cells were pre-incubated for 10 min 
at 37°C with WM (100 nM) or vehicle (0.1% (v/v) DMSO), before 
incubation for 1 h at 37°C with (a) insulin (1/tg/ml) or TPA (10 nM), 
or (b) insulin (1 ~g/ml), EGF (40 ng/ml) or AlI (100 nM); control cells 
received an equal volume addition of serum-free medium. RNA was 
prepared as described in the text, and aliquots (10 pg) were analysed 
by Northern blotting. The blots were probed simultaneously for cMG1 
and GAPDH, and the expression of cMGI is shown relative to that in 
the appropriate control cells, after correction for minor differences in 
the loading of RNA revealed by the scans of the GAPDH autoradi- 
ograph; the addition of WM did not affect he level of GAPDH expres- 
sion, but increased the basal expression of cMG1 by 68 + 24% 
(mean + S.E.M.; n = 7) compared with that in DMSO-treated cells. 
Similar results were obtained in two other experiments with insulin, 
such that the stimulation ofcMGl by insulin was reduced by WM from 
93 + 24% to 1 + 9% (n = 4), and in two additional experiments using 
IGF-I. Reprobing the blots for TIS11 mRNA showed that WM did not 
block the stimulation of TIS11 expression induced by TPA, EGF or 
All. 
cruitment [15]; the effects of EGF on PI-3,4,5-P 3levels, which 
may be mediated by association of the EGF receptor with the 
related erb-B3 protein [26], are less marked than those of ag- 
onists such as insulin [17]. 
The MAP kinases ERK-1 and ERK-2 are activated by vari- 
ous agonists including insulin [9,10,13], and have been shown 
to be involved in the stimulation of primary response genes 
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Fig. 3. Phosphorylation f MAP kinase ERK-2 in RIE-1 cells stimu- 
lated by insulin. Confluent, quiescent cells were pre-incubated for 10 
rain at 37°C with WM (100 nM) or forskolin (10/zM) plus IBMX (50 
pM) (F/I); cells indicated PKC- had been pretreated overnight with 
TPA to down-regulate PKC; control ceils were given 0.1% (v/v) DMSO. 
Insulin (1/.tg/ml) or vehicle was then added, and the incubation was 
continued at 37°C for 10 rain. Cell lysis, SDS/PAGE, Western blotting 
and analysis of ERK-2 were performed as described in the text. The 
positions of the shifted bands are indicated (p42/pp42). Similar esults 
were obtained in a second experiment ofthis design. 
activates the transcription factor NFkB [34]. The PKC-z 
isozyme is not affected by the TPA pretreatment used to deplete 
conventional PKC [35], and we have indeed found that such 
pretreatment with TPA, although inhibiting stimulation by AII 
[7], does not prevent he stimulation of cMG1 expression by 
insulin (Table 1). However, there are no obvious N FkB consen- 
sus sequences in about 1 kb of proximal 5'-flanking sequence 
of the cMG1 gene (A.N.C., J.C. Pascall, K.M. Hadfield and 
K,D.B., manuscript in preparation), and further work will 
therefore be required to elucidate the mechanism of activation 
of cMG1 at the gene level. It will also be interesting to deter- 
mine whether the inhibition by cyclic AMP of the stimulation 
of cMG1 expression by both insulin (Table 1) and EGF [7] 
results from an effect of cyclic AMP on a common signalling 
component, or on a negative regulatory element in the cMG1 
gene. 
[9,13,27]. The pathway from Raf-1 to ERK-2 is activated by 
receptor tyrosine kinases through Grb2, Sos and p21 ras 
[9,10,13], and in some cell types (but not others [28]) this activa- 
tion of ERK-2 has been shown to be blocked at Raf-1 by cyclic 
AMP analogues or cyclic AMP-elevating agents [28,29]. In 
addition, recent studies using WM have suggested that insulin 
may also activate this pathway through PI3K [30,31]. It was 
therefore possible that the inhibitory effects of cyclic AMP 
elevation and/or WM on insulin-stimulated cMG1 expression 
might be explained by inhibition of the MAP kinase pathway. 
Insulin stimulated a partial activation of ERK-2 in RIE- 1 cells, 
as revealed by the decreased electrophoretic mobility (Fig. 3) 
that is associated with its activation by phosphorylation [22,28]. 
However, this effect was not prevented when the cells were 
preincubated with WM or with IBMX plus forskolin (Fig. 3). 
These results indicate that the stimulation by insulin of ERK-2 
in RIE-1 cells is not mediated through PI3K, that the inhibition 
of insulin-stimulated cMG1 expression by WM is not due to 
inhibition of the ERK-2 pathway, and that we cannot use 
inhibition by cyclic AMP to deduce acontribution ofthis path- 
way to the insulin-stimulated expression of cMG1. The latter 
conclusion also applies to EGF-stimulated expression of 
cMG1, since the addition of IBMX plus forskolin did not affect 
the stimulation of ERK-2 by EGF (A.N.C., unpublished data). 
Taken together, our results uggest that insulin/IGF-I specif- 
ically activate cMG1 expression by a signalling pathway which 
involves WM-sensitive PI3K and is inhibited by cyclic AMP 
beyond a point of convergence with the separate signalling 
pathway stimulated by EGF. If there is a contribution of the 
MAP kinase pathway to cMG1 stimulation by insulin/IGF-I, 
then this is not sufficient for detectable stimulation to remain 
when the PI3K pathway is blocked. The signalling components 
downstream from PI3K remain to be determined. Recently, the 
rapamycin-sensitive pathway to p70 s6k been shown to be 
blocked by WM and LY294002, and thus may lie downstream 
of PI3K [19,30]; although p70 s6k is principally considered to be 
involved in the activation of translation rather than transcrip- 
tion, recent evidence suggests that it may also stimulate mem- 
bers of the CREM family of transcription modulators [32]. 
However, in preliminary experiments (not shown) rapamycin 
did not block the stimulation of cMG1 expression by insulin/ 
IGF-I, suggesting that the p70 ~6k pathway may not be involved. 
Another potential signalling pathway may be deduced from 
reports that PI 3,4,5-P3 stimulates PKC-z [33] and that PKC-z 
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